10
Participants
Start Date
August 31, 2013
Primary Completion Date
January 31, 2016
Study Completion Date
June 30, 2016
Vemurafenib
Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
Bevacizumab
Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
Cobimetinib
Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
NYU Clinical Cancer Center, New York
Columbia University Medical Center, New York
University of Pittsburgh Medical Center, Pittsburgh
Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Washington Cancer Institute at MedStar Washington Hospital Center, Washington D.C.
Harry and Jeannette Weinberg Cancer Institute at Franklin Square, Baltimore
Vanderbilt-Ingram Cancer Center, Nashville
OSU Comprehensive Cancer Center, Columbus
University of Colorado Cancer Center, Aurora
The Angeles Clinic, Los Angeles
University of Washington Medical Center, Seattle
Massachusetts General Hospital, Boston
Beth Israel Deaconess Medical Center (BIDMC), Boston
Dana-Farber Cancer Institute, Boston
Collaborators (1)
Genentech, Inc.
INDUSTRY
Melanoma Research Foundation Breakthrough Consortium
OTHER